The patient experience: Treatment with BCMA-directed therapies in relapsed MM
On March 5, 2026, the Multiple Myeloma Hub held a virtual symposium, titled Optimizing dosing of BCMA-directed therapies for improved quality of life in multiple myeloma. During the symposium, Rakesh Popat chaired a panel discussion featuring patient representative Lynn Williams, alongside faculty members Fredrik Schjesvold and Hang Quach, on real-world experience with belantamab mafodotin in multiple myeloma (MM).
In this discussion, Williams shares her experience of long-term treatment with belantamab mafodotin, including treatment burden, adverse events, and impact on quality of life. The…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.